{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:13:13Z","timestamp":1792512793094,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T00:00:00Z","timestamp":1553904000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010896","name":"International Cooperation and Exchange Programme","doi-asserted-by":"publisher","award":["81520108003"],"award-info":[{"award-number":["81520108003"]}],"id":[{"id":"10.13039\/501100010896","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670716"],"award-info":[{"award-number":["81670716"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["16JC1405800"],"award-info":[{"award-number":["16JC1405800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12943-019-0977-3","type":"journal-article","created":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T05:01:59Z","timestamp":1553922119000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1\/PD-L1-mediated lymphoma cell interaction with CD8+T cells"],"prefix":"10.1186","volume":"18","author":[{"given":"Zhong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Juan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Qin","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1704-4491","authenticated-orcid":false,"given":"Wei-Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,30]]},"reference":[{"key":"977_CR1","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1038\/leu.2016.135","volume":"30","author":"D Juskevicius","year":"2016","unstructured":"Juskevicius D, Lorber T, Gsponer J, Perrina V, Ruiz C, Stenner-Liewen F, Dirnhofer S, Tzankov A. Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis. Leukemia. 2016;30:2385\u201395.","journal-title":"Leukemia"},{"key":"977_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","volume":"13","author":"CL Batlevi","year":"2016","unstructured":"Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13:25\u201340.","journal-title":"Nat Rev Clin Oncol"},{"key":"977_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27:111\u201322.","journal-title":"Immunity"},{"key":"977_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"977_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nm0802-787","volume":"8","author":"GJ Freeman","year":"2002","unstructured":"Freeman GJ, Sharpe AH, Kuchroo VK. Protect the killer: CTLs need defenses against the tumor. Nat Med. 2002;8:787\u20139.","journal-title":"Nat Med"},{"key":"977_CR6","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-04-278739","volume":"116","author":"W Hobo","year":"2010","unstructured":"Hobo W, Maas F, Adisty N, de Witte T, Schaap N, van der Voort R, Dolstra H. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. Blood. 2010;116:4501\u201311.","journal-title":"Blood"},{"key":"977_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.cellsig.2014.12.003","volume":"27","author":"X Wang","year":"2015","unstructured":"Wang X, Li J, Dong K, Lin F, Long M, Ouyang Y, Wei J, Chen X, Weng Y, He T, Zhang H. Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia. Cell Signal. 2015;27:443\u201352.","journal-title":"Cell Signal"},{"key":"977_CR8","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","volume":"126","author":"J Kiyasu","year":"2015","unstructured":"Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D, Sugita Y, Yufu Y, Choi I, Abe Y, et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. Blood. 2015;126:2193\u2013201.","journal-title":"Blood"},{"key":"977_CR9","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.","journal-title":"Nat Commun"},{"key":"977_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2016.00003","volume":"6","author":"PR Kuninty","year":"2016","unstructured":"Kuninty PR, Schnittert J, Storm G, Prakash J. MicroRNA targeting to modulate tumor microenvironment. Front Oncol. 2016;6:3.","journal-title":"Front Oncol"},{"key":"977_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.4049\/jimmunol.1301309","volume":"192","author":"L Li","year":"2014","unstructured":"Li L, Zhang J, Diao W, Wang D, Wei Y, Zhang CY, Zen K. MicroRNA-155 and MicroRNA-21 promote the expansion of functional myeloid-derived suppressor cells. J Immunol. 2014;192:1034\u201343.","journal-title":"J Immunol"},{"key":"977_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2014-04-566778","volume":"125","author":"J Iqbal","year":"2015","unstructured":"Iqbal J, Shen Y, Huang X, Liu Y, Wake L, Liu C, Deffenbacher K, Lachel CM, Wang C, Rohr J, et al. Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood. 2015;125:1137\u201345.","journal-title":"Blood"},{"key":"977_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","volume":"375","author":"VA Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u201378.","journal-title":"N Engl J Med"},{"key":"977_CR14","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.celrep.2018.04.038","volume":"23","author":"E Stelekati","year":"2018","unstructured":"Stelekati E, Chen Z, Manne S, Kurachi M, Ali MA, Lewy K, Cai Z, Nzingha K, McLane LM, Hope JL, et al. Long-term persistence of exhausted CD8 T cells in chronic infection is regulated by MicroRNA-155. Cell Rep. 2018;23:2142\u201356.","journal-title":"Cell Rep"},{"key":"977_CR15","doi-asserted-by":"publisher","first-page":"4993","DOI":"10.1073\/pnas.1705327114","volume":"114","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Pillai RN, Yang S, Nasti TH, Akondy RS, Wieland A, Sica GL, Yu K, Koenig L, Patel NT, et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc Natl Acad Sci U S A. 2017;114:4993\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"977_CR16","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1073\/pnas.0602266103","volume":"103","author":"S Costinean","year":"2006","unstructured":"Costinean S, Zanesi N, Pekarsky Y, Tili E, Volinia S, Heerema N, Croce CM. Pre-B cell proliferation and lymphoblastic leukemia\/high-grade lymphoma in E (mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006;103:7024\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"977_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3727\/096504016X14685034103473","volume":"24","author":"FQ Zhu","year":"2016","unstructured":"Zhu FQ, Zeng L, Tang N, Tang YP, Zhou BP, Li FF, Wu WG, Zeng XB, Peng SS. MicroRNA-155 downregulation promotes cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. Oncol Res. 2016;24:415\u201327.","journal-title":"Oncol Res"},{"key":"977_CR18","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1182\/blood-2013-07-515254","volume":"123","author":"D Jiang","year":"2014","unstructured":"Jiang D, Aguiar RC. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-beta1\/SMAD5 signaling module. Blood. 2014;123:86\u201393.","journal-title":"Blood"},{"key":"977_CR19","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1038\/onc.2014.254","volume":"34","author":"HI Suzuki","year":"2015","unstructured":"Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene. 2015;34:3085\u201394.","journal-title":"Oncogene"},{"key":"977_CR20","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-17-1283","volume":"23","author":"Y Yin","year":"2017","unstructured":"Yin Y, Yao S, Hu Y, Feng Y, Li M, Bian Z, Zhang J, Qin Y, Qi X, Zhou L, et al. The immune-microenvironment confers Chemoresistance of colorectal Cancer through macrophage-derived IL6. Clin Cancer Res. 2017;23:7375\u201387.","journal-title":"Clin Cancer Res"},{"key":"977_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352.","journal-title":"Immunity"},{"key":"977_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cell.2005.06.030","volume":"122","author":"EJ Sontheimer","year":"2005","unstructured":"Sontheimer EJ, Carthew RW. Silence from within: endogenous siRNAs and miRNAs. Cell. 2005;122:9\u201312.","journal-title":"Cell"},{"key":"977_CR23","doi-asserted-by":"publisher","first-page":"18530","DOI":"10.1074\/jbc.M117.808121","volume":"292","author":"TB Huffaker","year":"2017","unstructured":"Huffaker TB, Lee SH, Tang WW, Wallace JA, Alexander M, Runtsch MC, Larsen DK, Thompson J, Ramstead AG, Voth WP, et al. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. J Biol Chem. 2017;292:18530\u201341.","journal-title":"J Biol Chem"},{"key":"977_CR24","doi-asserted-by":"publisher","first-page":"E1178","DOI":"10.1073\/pnas.1611299114","volume":"114","author":"A Rogel","year":"2017","unstructured":"Rogel A, Willoughby JE, Buchan SL, Leonard HJ, Thirdborough SM, Al-Shamkhani A. Akt signaling is critical for memory CD8(+) T-cell development and tumor immune surveillance. Proc Natl Acad Sci U S A. 2017;114:E1178\u201387.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"977_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1073\/pnas.1017340108","volume":"108","author":"K Adachi","year":"2011","unstructured":"Adachi K, Davis MM. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells. Proc Natl Acad Sci U S A. 2011;108:1549\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"977_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.bbrc.2008.10.007","volume":"377","author":"N Rahadiani","year":"2008","unstructured":"Rahadiani N, Takakuwa T, Tresnasari K, Morii E, Aozasa K. Latent membrane protein-1 of Epstein-Barr virus induces the expression of B-cell integration cluster, a precursor form of microRNA-155, in B lymphoma cell lines. Biochem Biophys Res Commun. 2008;377:579\u201383.","journal-title":"Biochem Biophys Res Commun"},{"key":"977_CR27","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","volume":"19","author":"BJ Chen","year":"2013","unstructured":"Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19:3462\u201373.","journal-title":"Clin Cancer Res"},{"key":"977_CR28","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","volume":"100","author":"S Gandini","year":"2016","unstructured":"Gandini S, Massi D, Mandala M. PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;100:88\u201398.","journal-title":"Crit Rev Oncol Hematol"},{"key":"977_CR29","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1084\/jem.20061496","volume":"203","author":"C Petrovas","year":"2006","unstructured":"Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, Precopio ML, Schacker T, Roederer M, Douek DC, Koup RA. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006;203:2281\u201392.","journal-title":"J Exp Med"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-019-0977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12943-019-0977-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-019-0977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,29]],"date-time":"2020-03-29T00:05:01Z","timestamp":1585440301000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-019-0977-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["977"],"URL":"https:\/\/doi.org\/10.1186\/s12943-019-0977-3","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,30]]},"assertion":[{"value":"25 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by Shanghai Rui Jin Hospital review board with informed consent obtained in accordance with the Declaration of Helsinki. Animals were used according to the protocols approved by Shanghai Rui Jin Hospital Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have agreed to publish this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"54"}}